Literature DB >> 17412872

Comparing subjective and digital image analysis HER2/neu expression scores with conventional and modified FISH scores in breast cancer.

I Skaland1, I Øvestad, E A M Janssen, J Klos, K H Kjellevold, T Helliesen, J P A Baak.   

Abstract

BACKGROUND: HER2/neu expression and fluorescence in situ hybridisation (FISH) amplification have therapeutic significance. AIMS: To compare subjective HER2/neu expression scores with digital image analysis (DIA) and conventional and modified FISH scores in breast cancer.
METHODS: Sixty HercepTest-immunostained breast carcinomas, prospectively scored as consensus 2+ and 3+ (DAKO protocol) by two observers, were analysed with DIA, and conventional (Vysis) and modified FISH scoring protocols.
RESULTS: With consensus scoring, 23 (38%) of the 60 cases were 2+ and 37 (62%) were 3+. Agreement with DIA scores was 100%. With conventional FISH scoring, 4 of the 3+ cases did not show amplification, but all of those negative cases had high HER2/neu copy numbers. With the modified FISH scoring protocol, all HercepTest immunohistochemical 3+ cases were amplified. Of the 2+ cases, 3 were amplified with the modified FISH protocol and 4 with the conventional FISH protocol.
CONCLUSIONS: Modified FISH scores were better correlated with HercepTest 3+ consensus and DIA scores than were conventional FISH scores. HER2/neu DIA scoring is a cost-effective supplementary tool in surgical pathology.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17412872     DOI: 10.1136/jcp.2007.046763

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  19 in total

1.  Significance of estrogen receptor 1 (ESR-1) gene imbalances in colon and hepatocellular carcinomas based on tissue microarrays analysis.

Authors:  Evangelos Tsiambas; Stavros N Georgiannos; Nikolaos Salemis; Despoina Alexopoulou; Sofia Lambropoulou; Blerta Dimo; Ioannis Ioannidis; Christos Kravvaritis; Andreas Karameris; Efstratios Patsouris; Spyridon Dourakis
Journal:  Med Oncol       Date:  2010-05-11       Impact factor: 3.064

2.  Image analysis of immunohistochemistry is superior to visual scoring as shown for patient outcome of esophageal adenocarcinoma.

Authors:  Annette Feuchtinger; Tabitha Stiehler; Uta Jütting; Goran Marjanovic; Birgit Luber; Rupert Langer; Axel Walch
Journal:  Histochem Cell Biol       Date:  2014-08-26       Impact factor: 4.304

3.  Observer variability in the interpretation of HER2/neu immunohistochemical expression with unaided and computer-aided digital microscopy.

Authors:  Marios A Gavrielides; Brandon D Gallas; Petra Lenz; Aldo Badano; Stephen M Hewitt
Journal:  Arch Pathol Lab Med       Date:  2011-02       Impact factor: 5.534

4.  Quantitative digital imaging analysis of HER2 immunohistochemistry predicts the response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma.

Authors:  Aidan C Li; Jing Zhao; Chao Zhao; Zhongliang Ma; Ramon Hartage; Yunxiang Zhang; Xiaoxian Li; Anil V Parwani
Journal:  Breast Cancer Res Treat       Date:  2020-01-30       Impact factor: 4.872

5.  Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq.

Authors:  Itay Tirosh; Benjamin Izar; Sanjay M Prakadan; Marc H Wadsworth; Daniel Treacy; John J Trombetta; Asaf Rotem; Christopher Rodman; Christine Lian; George Murphy; Mohammad Fallahi-Sichani; Ken Dutton-Regester; Jia-Ren Lin; Ofir Cohen; Parin Shah; Diana Lu; Alex S Genshaft; Travis K Hughes; Carly G K Ziegler; Samuel W Kazer; Aleth Gaillard; Kellie E Kolb; Alexandra-Chloé Villani; Cory M Johannessen; Aleksandr Y Andreev; Eliezer M Van Allen; Monica Bertagnolli; Peter K Sorger; Ryan J Sullivan; Keith T Flaherty; Dennie T Frederick; Judit Jané-Valbuena; Charles H Yoon; Orit Rozenblatt-Rosen; Alex K Shalek; Aviv Regev; Levi A Garraway
Journal:  Science       Date:  2016-04-08       Impact factor: 47.728

6.  Membrane connectivity estimated by digital image analysis of HER2 immunohistochemistry is concordant with visual scoring and fluorescence in situ hybridization results: algorithm evaluation on breast cancer tissue microarrays.

Authors:  Aida Laurinaviciene; Darius Dasevicius; Valerijus Ostapenko; Sonata Jarmalaite; Juozas Lazutka; Arvydas Laurinavicius
Journal:  Diagn Pathol       Date:  2011-09-23       Impact factor: 2.644

7.  Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring.

Authors:  Anthony E Rizzardi; Arthur T Johnson; Rachel Isaksson Vogel; Stefan E Pambuccian; Jonathan Henriksen; Amy Pn Skubitz; Gregory J Metzger; Stephen C Schmechel
Journal:  Diagn Pathol       Date:  2012-06-20       Impact factor: 2.644

8.  Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situ hybridization (FISH): pathologist assessment compared to quantitative image analysis.

Authors:  Gulisa Turashvili; Samuel Leung; Dmitry Turbin; Kelli Montgomery; Blake Gilks; Rob West; Melinda Carrier; David Huntsman; Samuel Aparicio
Journal:  BMC Cancer       Date:  2009-05-29       Impact factor: 4.430

9.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; David G Hicks; Mitch Dowsett; Lisa M McShane; Kimberly H Allison; Donald C Allred; John M S Bartlett; Michael Bilous; Patrick Fitzgibbons; Wedad Hanna; Robert B Jenkins; Pamela B Mangu; Soonmyung Paik; Edith A Perez; Michael F Press; Patricia A Spears; Gail H Vance; Giuseppe Viale; Daniel F Hayes
Journal:  Arch Pathol Lab Med       Date:  2013-10-07       Impact factor: 5.534

10.  Quantitative Image Analysis for Tissue Biomarker Use: A White Paper From the Digital Pathology Association.

Authors:  Haydee Lara; Zaibo Li; Esther Abels; Famke Aeffner; Marilyn M Bui; Ehab A ElGabry; Cleopatra Kozlowski; Michael C Montalto; Anil V Parwani; Mark D Zarella; Douglas Bowman; David Rimm; Liron Pantanowitz
Journal:  Appl Immunohistochem Mol Morphol       Date:  2021-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.